DENTSPLY SIRONA Inc.
NASDAQ:XRAYMedical - Instruments & Supplies
+$0.19 today
- Market cap
- $1.70B
- Beta
- 0.91
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.14
- Dividend yield
- 6.27%
Volume 5.40M
Average 4.70M
XRAY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
DENTSPLY SIRONA Inc.NASDAQ: XRAY
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$119M, compared with $123M a year earlier. Trailing-twelve-month financing cash flow was -$322M. Over 3 fiscal years it compounded at -37.6% a year.
Context
- Financing cash flow amounted to 2.2% of revenue in FY2025, down 5.8 pp from a year earlier.
- Financing cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$119M or moves back toward the trailing-twelve-month quarterly average of -$80.5M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (80M) USD
- Year-over-year change
- +73.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (80M) | +73.5% |
| FY2024 | 2024-12-31 | (302M) | +1.6% |
| FY2023 | 2023-12-31 | (307M) | +6.7% |
| FY2022 | 2022-12-31 | (329M) | +13.2% |
| FY2021 | 2021-12-31 | (379M) | — |
Financing Cash Flow vs competitors
How XRAY compares with its peers on the latest reported figures
- XRAY's LTM Mar 2026 financing cash flow of $322M is the 2nd largest of the 4 companies compared; the peer median is $277.1M.
- Its year-over-year change of +95.2% is the 2nd highest of 4, against a peer median of -44.1%.
- Financing cash flow amounts to 8.7% of revenue for XRAY, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381M | +632.7% | -29.4% | 2.8% | |
| LTM Mar 2026 | $322M | +95.2% | -37.6% | 8.7% | |
| LTM Jun 2026 | $277.1M | -44.1% | -2.5% | 6.7% | |
| LTM Oct 2026 | $25.2M | -82.8% | — | 0.9% | |
| Peer median (excluding XRAY) | $277.1M | -44.1% | -15.9% | 2.8% | |
Competitors are the stored peer set for XRAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 411M | (950M) | (132M) | (910M) | (598M) |
| Depreciation & Amortization | 346M | 328M | 343M | 349M | 352M |
| Deferred Income Tax | (25M) | (228M) | (130M) | (136M) | 30M |
| Stock-Based Compensation | 48M | 59M | 46M | 39M | 33M |
| Change in Working Capital | (126M) | (78M) | (89M) | 95M | (222M) |
| Accounts Receivables | (117M) | 85M | (58M) | 104M | (91M) |
| Inventory | (64M) | (141M) | 6M | 17M | (17M) |
| Accounts Payables | (49M) | 30M | 14M | (30M) | 11M |
| Other Working Capital | 104M | (52M) | (51M) | 4M | (125M) |
| Other Non-Cash Items | 3M | 1.39B | 339M | 1.02B | 640M |
| Operating Cash Flow | 657M | 517M | 377M | 461M | 235M |
| Capital Expenditures | (142M) | (149M) | (149M) | (180M) | (131M) |
| Acquisitions (Net) | (220M) | 0 | 13M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 2M | 13M | 0 | 0 | 0 |
| Other Investing Activities | 2M | (2M) | 47M | (17M) | (1M) |
| Investing Cash Flow | (358M) | (138M) | (89M) | (197M) | (132M) |
| Debt Repayment | (102M) | (60M) | 119M | 90M | 54M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (200M) | (150M) | (300M) | (250M) | 0 |
| Dividends Paid | (92M) | (104M) | (116M) | (126M) | (128M) |
| Other Financing Activities | 15M | (15M) | (10M) | (16M) | (6M) |
| Financing Cash Flow | (379M) | (329M) | (307M) | (302M) | (80M) |
| Effect of Forex Changes | (19M) | (24M) | (12M) | (24M) | 31M |
| Net Change in Cash | (99M) | 26M | (31M) | (62M) | 54M |
| Free Cash Flow | 515M | 368M | 228M | 281M | 104M |
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
Intrinsic Alpha fair value
Locked
Current Price
$8.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.